Detailed Narrative
Strategic Growth Drivers
Zoetis's strategy focuses on scientific innovation and commercial excellence, driving long-term growth in key franchises like Simparica, Librela, Solensia, and Dermatology. The company leverages its global scale and omnichannel strategy to meet evolving customer preferences and ensure broad access to treatments, while championing the role of veterinarians. This approach ensures market leadership and sustained above-market growth.
Companion Animal Portfolio Strength
The Companion Animal portfolio achieved 14% operational revenue growth for the full year, led by the Simparica franchise, which generated $1.4 billion in revenue with 28% operational growth. OA Pain mAbs Librela and Solensia combined for $581 million in revenue, growing 80% operationally. Librela's U.S. launch was the most successful in company history, reaching blockbuster status rapidly and becoming the fourth largest product in the U.S. pet care portfolio.
Livestock Portfolio Performance
The Livestock portfolio delivered strong 5% operational revenue growth for the full year, exceeding initial expectations and reaching $2.9 billion in sales. This was achieved despite the strategic divestiture of the Medicated Feed Additive (MFA) product portfolio and related assets in Q4. The divestiture aims to streamline focus on high-growth, high-value areas like innovative vaccines and antibiotic alternatives, aligning with long-term strategy.
Market Expansion Opportunities
Significant market expansion opportunities exist across key therapeutic areas. The global triple combination market, led by Simparica Trio, is projected to more than double from $2 billion to $4.5 billion by 2028. In dermatology, with 20 million untreated or under-treated dogs globally, the total addressable market is projected to grow to $2.5 billion by 2028. OA pain management also presents substantial growth, with nearly 40% of dogs suffering from OA.
Pipeline and Future Innovation
Zoetis expects at least one major approval annually over the next several years, with multiple potential blockbusters in its pipeline. This includes therapies for chronic kidney disease, a $3 billion to $4 billion market, and oncology, a $1.2 billion to $1.7 billion market. The development of long-acting formulations is also anticipated to significantly improve compliance and market penetration for existing and future treatments.
Capital Allocation and Shareholder Returns
In 2024, Zoetis demonstrated its commitment to shareholder returns by repurchasing $1.9 billion of shares, the most in its history, and approving a new multi-year $6 billion share repurchase program. The company also increased its dividend rate by 15%, distributing $786 million to shareholders. In total, over $2.6 billion was returned to shareholders in 2024, an increase of over $800 million versus the prior year.